Current status of androgen receptor-splice variant 7 inhibitor niclosamide in castrate-resistant prostate-cancer

Navid Sobhani, Daniele Generali, Alberto D'Angelo, Michele Aieta, Giandomenico Roviello

Research output: Contribution to journalReview article

5 Citations (Scopus)
12 Downloads (Pure)

Abstract

Castrate-Resistant Prostate-Cancer (CRPC) is one of the most common malignancies occurring in men. Unfortunately, even if several recently approved agents clinically improved the outcome of CRPC patients, none of these is curative especially for a splice version of the Androgen Receptor (AR) AR-V7, which is a variant of the receptor constitutively activated and does not require the presence of androgens for the activation AR down-stream pathways. Since high AR-V7 expression is one of the most common features of CRPC, targeting this receptor variant is considered as one of the most promising strategies for treating this disease. Therefore anti-AR-V7 molecules could lead to a potential shift in paradigm in the treatment of CRPC. Niclosamide, an already FDA-approved anti-helminthic drug, was identified as a potent AR-V7 inhibitor in prostate cancer cells. Due to the recent positive preclinical results, niclosamide may be an interesting and novel type of targeted treatments for CRPC. This mini-review outlines the most recent pre- and clinical- data on the current status of niclosamide in the treatment of ARV7-positive CRPC patients.

Original languageEnglish
Pages (from-to)1133-1137
Number of pages5
JournalInvestigational New Drugs
Volume36
Issue number6
Early online date7 Aug 2018
DOIs
Publication statusPublished - 31 Dec 2018

Cite this

Current status of androgen receptor-splice variant 7 inhibitor niclosamide in castrate-resistant prostate-cancer. / Sobhani, Navid; Generali, Daniele; D'Angelo, Alberto; Aieta, Michele; Roviello, Giandomenico.

In: Investigational New Drugs, Vol. 36, No. 6, 31.12.2018, p. 1133-1137.

Research output: Contribution to journalReview article

Sobhani, Navid ; Generali, Daniele ; D'Angelo, Alberto ; Aieta, Michele ; Roviello, Giandomenico. / Current status of androgen receptor-splice variant 7 inhibitor niclosamide in castrate-resistant prostate-cancer. In: Investigational New Drugs. 2018 ; Vol. 36, No. 6. pp. 1133-1137.
@article{f559490d05be429a8d8feeac090b829f,
title = "Current status of androgen receptor-splice variant 7 inhibitor niclosamide in castrate-resistant prostate-cancer",
abstract = "Castrate-Resistant Prostate-Cancer (CRPC) is one of the most common malignancies occurring in men. Unfortunately, even if several recently approved agents clinically improved the outcome of CRPC patients, none of these is curative especially for a splice version of the Androgen Receptor (AR) AR-V7, which is a variant of the receptor constitutively activated and does not require the presence of androgens for the activation AR down-stream pathways. Since high AR-V7 expression is one of the most common features of CRPC, targeting this receptor variant is considered as one of the most promising strategies for treating this disease. Therefore anti-AR-V7 molecules could lead to a potential shift in paradigm in the treatment of CRPC. Niclosamide, an already FDA-approved anti-helminthic drug, was identified as a potent AR-V7 inhibitor in prostate cancer cells. Due to the recent positive preclinical results, niclosamide may be an interesting and novel type of targeted treatments for CRPC. This mini-review outlines the most recent pre- and clinical- data on the current status of niclosamide in the treatment of ARV7-positive CRPC patients.",
author = "Navid Sobhani and Daniele Generali and Alberto D'Angelo and Michele Aieta and Giandomenico Roviello",
year = "2018",
month = "12",
day = "31",
doi = "10.1007/s10637-018-0653-2",
language = "English",
volume = "36",
pages = "1133--1137",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - Current status of androgen receptor-splice variant 7 inhibitor niclosamide in castrate-resistant prostate-cancer

AU - Sobhani, Navid

AU - Generali, Daniele

AU - D'Angelo, Alberto

AU - Aieta, Michele

AU - Roviello, Giandomenico

PY - 2018/12/31

Y1 - 2018/12/31

N2 - Castrate-Resistant Prostate-Cancer (CRPC) is one of the most common malignancies occurring in men. Unfortunately, even if several recently approved agents clinically improved the outcome of CRPC patients, none of these is curative especially for a splice version of the Androgen Receptor (AR) AR-V7, which is a variant of the receptor constitutively activated and does not require the presence of androgens for the activation AR down-stream pathways. Since high AR-V7 expression is one of the most common features of CRPC, targeting this receptor variant is considered as one of the most promising strategies for treating this disease. Therefore anti-AR-V7 molecules could lead to a potential shift in paradigm in the treatment of CRPC. Niclosamide, an already FDA-approved anti-helminthic drug, was identified as a potent AR-V7 inhibitor in prostate cancer cells. Due to the recent positive preclinical results, niclosamide may be an interesting and novel type of targeted treatments for CRPC. This mini-review outlines the most recent pre- and clinical- data on the current status of niclosamide in the treatment of ARV7-positive CRPC patients.

AB - Castrate-Resistant Prostate-Cancer (CRPC) is one of the most common malignancies occurring in men. Unfortunately, even if several recently approved agents clinically improved the outcome of CRPC patients, none of these is curative especially for a splice version of the Androgen Receptor (AR) AR-V7, which is a variant of the receptor constitutively activated and does not require the presence of androgens for the activation AR down-stream pathways. Since high AR-V7 expression is one of the most common features of CRPC, targeting this receptor variant is considered as one of the most promising strategies for treating this disease. Therefore anti-AR-V7 molecules could lead to a potential shift in paradigm in the treatment of CRPC. Niclosamide, an already FDA-approved anti-helminthic drug, was identified as a potent AR-V7 inhibitor in prostate cancer cells. Due to the recent positive preclinical results, niclosamide may be an interesting and novel type of targeted treatments for CRPC. This mini-review outlines the most recent pre- and clinical- data on the current status of niclosamide in the treatment of ARV7-positive CRPC patients.

U2 - 10.1007/s10637-018-0653-2

DO - 10.1007/s10637-018-0653-2

M3 - Review article

C2 - 30083960

VL - 36

SP - 1133

EP - 1137

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 6

ER -